BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 31034644)

  • 1. Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer.
    Chen Y; Bi F; An Y; Yang Q
    J Cell Biochem; 2019 Sep; 120(9):14444-14454. PubMed ID: 31034644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
    Chen H; Tian X; Luan Y; Lu H
    Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a RNA-Seq Based 8-Long Non-Coding RNA Signature Predicting Survival in Esophageal Cancer.
    Fan Q; Liu B
    Med Sci Monit; 2016 Dec; 22():5163-5172. PubMed ID: 28028307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
    Yan J; Zhou C; Guo K; Li Q; Wang Z
    J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer.
    Feng S; Yin H; Zhang K; Shan M; Ji X; Luo S; Shen Y
    J Ovarian Res; 2022 Jan; 15(1):10. PubMed ID: 35057848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
    Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
    Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
    Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.
    Fan ZY; Liu W; Yan C; Zhu ZL; Xu W; Li JF; Su L; Li C; Zhu ZG; Liu B; Yan M
    Tumour Biol; 2016 Oct; 37(10):13265-13277. PubMed ID: 27460075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways.
    Jiao Y; Li Y; Ji B; Cai H; Liu Y
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):439-447. PubMed ID: 31826070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer.
    Li J; Wang W; Xia P; Wan L; Zhang L; Yu L; Wang L; Chen X; Xiao Y; Xu C
    Int J Cancer; 2018 Nov; 143(9):2150-2160. PubMed ID: 29707762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of a competing endogenous RNA network reveals an 11-lncRNA prognostic signature in ovarian cancer.
    Zhang Y; Zhou H; Zhang M; Xing L; Yang C; Xia B; Lou G
    Aging (Albany NY); 2020 Nov; 12(24):25153-25171. PubMed ID: 33223503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
    Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
    J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
    Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
    Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
    Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
    Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.